New cancer drugs such as bevacizumab (BEV) provide hope for patients worldwide. These opportunities-accompanied by expensive price tags-require evaluations of benefits, toxicities, and costs. One aspect is that not all toxicities are created equal; some patients who experience toxicities are treated as inpatients and others are not. Carroll et al 1 address this concept as they report on patterns of use, clinical toxicities, and hospitalizations associated with carboplatin, paclitaxel, and BEV (CPB) treatment administered to persons with stages IIIB/IV non-smallcell lung cancer (NSCLC).
CPB. One could postulate that more toxicities, and more hospitalizations for toxicity management, could have occurred in other health care settings. On an ironic note, this study demonstrates that when CPB therapy is administered to patients without specific contraindications to BEV, BEV still causes serious adverse drug reactions.
NSCLC imposes a substantial burden on patients and health care systems as a result of its high incidence rate and poor survival rates. Carboplatin and paclitaxel are inexpensive, especially when compared with BEV. In a recent systematic review of first-line treatment of advanced NSCLC, BEV had an incremental cost-effectiveness ratio greater than $150,000 per quality-adjusted life-year, far higher than the generally agreed-upon threshold of $50,000 to $100,000 per quality-adjusted life-year. 2, 3 Resources are limited in every country, and it is likely that only developed countries with large health care budgets can afford to offer CPB treatment broadly for persons with advanced NSCLC. Carroll et al also suggested that even in well-resourced settings such as the United States, CPB treatment should be judiciously administered such that if toxicity occurs, it can be managed on an outpatient basis.
The findings of Carroll et al 1 have international implications, building on analyses of toxicities and costs recently reported for targeted cancer therapies. 4, 5 Whereas toxicities associated with CPB may be relatively constant from country to country, therapy-related hospitalizations will differ because of variations both between and within health systems. Although this study is directed toward oncologists and decision makers in the United States, other audiences will benefit from it. The authors have made a terrific beginning in analyzing the impact of a new cancer regimen for NSCLC in a community setting in the United States. Updates are essential as experience with this regimen matures internationally and as new NSCLC regimens are introduced. For the time being, caveat emptor to clinicians who choose to administer CPB therapy to patients with NSCLC; toxicities are significant with this regimen even among younger patients with few comorbid illnesses. 
